To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
- Disease/Condition
- Psoriasis
- Drug/Device/Intervention
- Hemay005
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Start date
- Apr 01, 2024
- End date
- Dec 01, 2024
- Enrollment
- 24 participants
Relevant pharmacokinetic parameters，Peak Plasma Concentration（Cmax）,Relevant pharmacokinetic parameters，Area under the plasma concentration versus time curve（AUC0-t）,Relevant pharmacokinetic parameters，Area under the curve from time 0 extrapolated to infinite time (AUC0-inf),Relevant pharmacokinetic parameters，half-life (T1/2),Relevant pharmacokinetic parameters，clearance (CL/F),Relevant pharmacokinetic parameters，volume of distribution (Vz/F)
The purpose of this study was to evaluate the pharmacokinetics of Hemay 005 tablets in
 subjects with mild, moderate liver impairment and normal liver function, and to provide a
 basis for the formulation of clinical medication regimens for patients with liver impairment.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06376474
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06376474 through Pure Global AI's free database. This Phase 1 trial is sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd and is currently Not yet recruiting. The study focuses on Psoriasis. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.